

## Special Issue

# Artificial Intelligence in Ocular Oncology

### Message from the Guest Editor

There are many kinds of ocular tumors, most of which are rare. Several are life threatening or associated with lethal syndromes. Diagnosis can be challenging because each tumor can show a wide variety of clinical manifestations. Multimodal imaging can be invaluable but only if the clinician has the skill to interpret the results correctly. Relevant information may be forgotten by the clinician, or out of date, or not easily found in the published literature. Artificial intelligence promises to help non-experts diagnose and manage patients with ocular tumors when support from an ocular oncologist is not possible. Where ocular oncology services are available, artificial intelligence may help avoid non-essential referrals, saving time and money both for patients and healthcare services. As with other technologies, clinicians must be aware of the limitations of artificial intelligence and the need to check its guidance by referring to peer-reviewed and authoritative texts. This Special Issue provides a forum for recent advances in artificial intelligence in ocular oncology.

### Guest Editor

Prof. Dr. Bertil E. Damato

Ocular Oncology Service, Moorfields Eye Hospital, City Rd, London EC1V 2PD, UK

### Deadline for manuscript submissions

20 March 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/249012](https://mdpi.com/si/249012)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)